DeepTek.ai secures US FDA clearance for its ground-breaking chest X-ray AI Solution

israel: Israel's judicial proposals prompt startups to relocate: government agency


DeepTek.ai, the leading medical imaging Artificial Intelligence (AI) company in India, has announced that it has received clearance from the US Food and Drug Administration (FDA) for its revolutionary chest X-ray AI solution CXR Analyzer. This advanced technology uses deep learning algorithms to detect abnormalities in chest X-rays. It identifies, categorises, and highlights suspicious areas automatically, aiding clinicians in making precise interpretations.

Unlike traditional point AI solutions identifying a specific pathology, DeepTek’s chest X-ray AI covers the entire chest area, offering analysis for a broader range of lung, pleural, and cardiac pathologies and foreign bodies/hardware on the chest. It’s compatible with various X-ray machines, including hospital-based, mobile, portable, hand-held, and ultra-portable units, making it versatile and powerful.

This AI model accelerates decision-making by detecting and locating suspicious lesions in chest X-rays, which are crucial for diagnosing conditions like lung infections, cancer, and chronic lung diseases. In a world with 3.5 billion annual X-rays, 1.5 billion are chest X-rays, making the need for precise interpretation essential. The shortage of radiologists further emphasises the role of AI in addressing this challenge.

Dr Amit Kharat, Co-Founder of DeepTek.ai, quoted, “DeepTek CXR Analyzer v1.0 is a game-changer, reducing a radiologist’s workload by an impressive 30-50%. With FDA clearance, we’re not only accessing the vast US healthcare market but also impacting lives globally. By swiftly identifying lung abnormalities and offering precise mapping, we’re unlocking a world of possibilities for improved outcomes across various medical specialities.”

“The radiology AI market is growing at around 34% CAGR and is anticipated to reach approximately $30 billion by 2030. Our entire product suite is now cleared by the US FDA, and coupled with the marquee customers we have successfully established, this positions us as a leader in this space”, said Ajit Patil, Co-Founder of DeepTek.ai.

DeepTek’s AI solutions have been transforming healthcare in India and the Asia-Pacific region by providing increased access to quality care at a lower cost. Over 500 hospitals and imaging centres use DeepTek’s AI solutions, impacting the lives of 1,00,000 people monthly. More than half a million people have been screened using DeepTek’s chest X-Ray Analyzer for tuberculosis screening. In Singapore, DeepTek’s US FDA-approved platform, Augmento, has been deployed as the national radiology AI platform, boosting productivity and quality of care across public hospitals.

Discover the stories of your interest


With its operations in Pune, DeepTek has about 200 members and partners like TATA Capital and NTT DATA Japan.For more information, visit: www.deeptek.ai

Disclaimer – The above content is non-editorial, and ET hereby disclaims any and all warranties, expressed or implied, relating to it, and does not guarantee, vouch for or necessarily endorse any of the content.

Stay on top of technology and startup news that matters. Subscribe to our daily newsletter for the latest and must-read tech news, delivered straight to your inbox.



Source link

Online Company Registration in India

Leave a Reply

Your email address will not be published. Required fields are marked *